* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Aeterna Zentaris

                   

BUYINS.NET: KERX, MITI, OTEX, SDTH, SVNT, INBG Have Also Been Added To Naked Short List Today

tmcnet.com
Jul 2, 2008 24 related
        

BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Micromet Inc. (NASDAQ: MITI), Open...

add comment

AEterna Zentaris Inc divests Quebec City building

m2.com
Jun 30, 2008
        

AEterna Zentaris Inc (NASDAQ:AEZS) (TSX:AEZ), a biopharmaceutical company focused on endocrine therapy and oncology, declared on 27 June that the company has closed the sale of its Quebec City property for a purchase price of...

add comment
                   

Solid Tumor Space Companies Examined in Wall Street Transcript Biotechnology Report (Wall Street...

yahoo.com
Jun 27, 2008 3 related
        

67 WALL STREET, New York - The Wall Street Transcript has just published its Biotechnology issue, a report offering a timely review of the sector to serious investors and industry executives. The full issue is available by...

add comment

AEterna Zentaris Sells Quebec City Building for $7.1 million

tmcnet.com
Jun 27, 2008 4 related
        

Attention Business/Financial Editors All amounts are in U.S. dollars QU?BEC CITY, June 27 /CNW Telbec/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ;), a global biopharmaceutical company focused on endocrine therapy and...

add comment
                   

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients...

yahoo.com
Jun 3, 2008 2 related
        

Keryx Biopharmaceuticals, Inc. today announced that phase 2 results of perifosine in patients with relapsed/refractory Waldenstroms macroglobulinemia was presented at the 44th Annual Meeting of the American Society of Clinical Oncology.

add comment
                   

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical...

drugs.com
Jun 3, 2008 3 related
        

Phase 2 Results of Perifosine in the Treatment of Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia to be presented Tomorrow, Tuesday, June 3rd at 12:00pm in Room E450a NEW YORK, June 02, 2008 /PRNewswire-FirstCall/...

add comment

AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in...

bionity.com
May 15, 2008 8 related
        

16 May 2008 - AEterna Zentaris Inc. reported dosing has commenced in the safety study of the Company's Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH). Cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist, is the Company's flagship...

add comment

Paladin Reports 2008 First Quarter Financial Results

drugpolicycentral.com
May 15, 2008
        

Entered into a Canadian Co-Promotion Agreement for Tridural(TM) once-daily tramadol with Nycomed Canada Inc. Also during the quarter, Paladin and Nycomed entered into a Canadian Co-Promotion Agreement for Tridural(TM) once-daily tramadol product. (Thu May 15 04:48:51 2008...

add comment

The Maybach Journal: AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results

tmcnet.com
May 7, 2008 31 related
        

The Maybach Journal: AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results ... MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. They recently announced the following: Wednesday, May 7, 2008...

add comment
genengnews.com: Genetic Engineering genengnews.com

Warnex Appoints Two New Directors: Gilles Gagnon and Mattie Chinks

tmcnet.com
Apr 30, 2008 1 related
        

Warnex Appoints Two New Directors: Gilles Gagnon and Mattie Chinks ... LAVAL, QUEBEC, April 30 / MARKET WIRE/ -- Warnex Inc. (TSX: WNX) is pleased to announce that, following it Annual General Meeting of Shareholders, Mr. Gilles Gagnon and Mr. Mattie Chinks have joined...

add comment